Clinical Trials on Locally Advanced Non-small Cell Lung Cancer in Japan

Total 433 results

Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907)

Non-Small Cell Lung Cancer

United States, Canada, Japan, Romania, South Africa
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Ovarian Cancer | Advanced Solid Tumors

Japan, Korea, Republic of
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Nonsquamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Chile, China, France, Germany, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, United Kingdom
Japan Multinational Trial Organization

Completed

Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

Japan
Sumitomo Pharma Co., Ltd.

Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Small-cell Lung Cancer

Japan
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Completed

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01)

Non-Small Cell Lung Cancer

United States, Spain, Japan, Netherlands, France
Hoffmann-La Roche

Active, not recruiting

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung

United States, Korea, Republic of, United Kingdom, Australia, France, Italy, Spain, Japan, Brazil, China, Germany, Poland, Thailand, Israel, Switzerland, Taiwan, Austria, Russian Federation, Ukraine, Hungary, Serbia, Slovenia, South... and more
Shiga University
University of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaborators

Unknown

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
Novartis Pharmaceuticals

Completed

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Cancer

United States, United Kingdom, Japan, Norway, Spain, Taiwan, France, Germany, Korea, Republic of, Italy, Netherlands
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand
Taiho Oncology, Inc.

Recruiting

A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351)

Non-Small Cell Lung Cancer

United States, France, Italy, Korea, Republic of, Japan, Spain, Germany, Netherlands, United Kingdom
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
AbbVie

Terminated

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Cancer | Non Small Cell Lung Cancer | Acute Myeloid Leukemia (AML)

United States, France, Israel, Japan, United Kingdom
Ariad Pharmaceuticals
Takeda

Active, not recruiting

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

ALK-positive Advanced NSCLC

Korea, Republic of, United States, Spain, Taiwan, Canada, Hong Kong, China, Sweden, Australia, Italy, Japan, Germany, Netherlands, France, Austria
Taiho Pharmaceutical Co., Ltd.

Recruiting

AB122 Platform Study

Gastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid Tumor

Japan
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, Italy, France, Japan, Taiwan, Netherlands, Australia, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
National Hospital Organization Kinki-chuo Chest...

Unknown

Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

Lung Cancer

Japan
GlaxoSmithKline

Completed

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor (PEARL)

Lung Cancer, Non-Small Cell

United States, Estonia, France, Korea, Republic of, United Kingdom, Germany, Japan, Russian Federation, Poland
Pfizer

Completed

Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Terminated

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Non-Small Cell Lung Cancer

Italy, Singapore, Spain, Germany, Korea, Republic of, United States, Belgium, France, Netherlands, Japan
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
AstraZeneca

Completed

Iressa 2nd Line Phase III Study in Japan

Non-Small Cell Lung Cancer

Japan
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
Novartis Pharmaceuticals

Completed

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Non-Small Cell Lung Cancer

Canada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb

Completed

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Non-Small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
Dizal Pharmaceuticals

Active, not recruiting

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Non-Small Cell Lung Cancer

Korea, Republic of, Spain, United States, France, Taiwan, Italy, China, Argentina, Australia, Malaysia, Canada, Japan, Chile
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Spain, China, Denmark, Italy, Germany, Mexico, Poland, United States, Brazil, Peru, Thailand, Serbia, Switzerland, Japan, Turkey, Netherlands, Austria, Taiwan, Russian Federation, Ukraine, Greece
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Belgium, Canada, Australia, Brazil, China, Japan, Taiwan, Israel, France, Singapore, Germany, Italy, Spain, Thailand, Sweden, Turkey, Colombia, Costa Rica, Hong Kong, Poland, Chile, United Kingdom, New... and more
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2)

Non-Small Cell Lung Cancer

United States, Spain, China, Italy, Turkey, Argentina, United Kingdom, Canada, Germany, Brazil, Vietnam, Thailand, Poland, Russian Federation, Japan, Korea, Republic of, Taiwan, Malaysia, Singapore, Romania
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Belgium, China, France, Netherlands, Japan, Hungary, Russian Federation, Taiwan, Ireland, Romania, Israel, Latvia, Italy, Portugal, Austria, Bulgaria, Chile, Ukraine, Argenti... and more
AstraZeneca
Arcus Biosciences, Inc.

Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Non-Small Cell Lung Cancer

Korea, Republic of, Philippines, United States, Belgium, Hungary, India, Norway, United Kingdom, France, Canada, Germany, Japan, Malaysia, Taiwan, Greece, Italy, Mexico, Turkey, South Africa, Chile, Brazil, Romania, Spain, Switzerland, ... and more
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Germany, Italy, Spain, Canada, Poland, Thailand, Vietnam, Korea, Republic of, Hungary, Japan, Mexico, Peru, Turkey, United Kingdom, Taiwan, Chile, Australia, Israel, South Africa, Netherlands, Greece, Sin... and more

Clinical Trials on Locally Advanced Non-small Cell Lung Cancer in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations